When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mainly used to make the site work as you expect it to. The information does not directly identify you but can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. However, blocking some types of cookies may impact your experience of the site. You can find more information, including a detailed cookie explanation, on our Cookie Policy.
Test
| When | Where | Title | Presenter |
|---|---|---|---|
| Apr 11, 2022 (9:00am) | CT107 | Correlation of biomarkers and clinical benefit of intratumoral BO112 and pembrolizumab in patients with anti PD1 refractory melanoma | Beatriz García-Peláez, PhD |
| Apr 11, 2022 (9:00am) | CT109 | Radiomic features in tumor assessment, preliminary results from a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with anti PD1 refractory melanoma | Ángel Alberich-Bayarri, PhD |
| April 12, 2022 (10:46-11:01am) | Hall B-C, Convention Center | Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: final results of SPOTLIGHT-203 phase 2 study | Iván Márquez-Rodas MD, PhD |